AbbVie ABBV

AbbVie reports Q3 2026 results

Item 2.02 Reports results

Form: 8-K
Filed: Oct 30, 2026, 7:51 am ET
Importance: Major
Accession: 0001551152-26-000033

Exhibit 99.1 includes the press release
Item 2.02 covers financial results

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the app Get the app View on EDGAR

The reading, claim by claim

The filing includes a press release with details on the company's financial performance.
The press release states that AbbVie reported third-quarter diluted EPS of $2.37 on a GAAP basis and adjusted diluted EPS of $3.82.
It also mentions net revenues of $17.404 billion, an increase of 10.3 percent on a reported basis.
The results include an unfavorable impact of $0.11 per share related to acquired IPR and milestones expense.
The Immunology portfolio generated $9.165 billion, up 16.3 percent on a reported basis.
The Neuroscience portfolio reported $3.389 billion, an increase of 19.4 percent on a reported basis.
The Oncology portfolio reported $1.696 billion, a 0.8 percent increase on a reported basis.

7 of 8 claims matched the filing text.

Not found in the filing text

The report also noted the impact of acquired IPR and milestones expense on earnings.

From the filing

Item 2.02 Results of Operations and Financial Condition

On October 30, 2026, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2026.¹ ¹A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.¹

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit

99.1

Press Release dated October 3 0 , 2026 (furnished pursuant to Item 2.02).

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date: October 30, 2026 By: /s/ Scott T. Reents

Scott T. Reents

Executive Vice President,

Chief Financial Officer

PRESS RELEASE

AbbVie Reports Third-Quarter 2026 Financial Results

Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent² These Results Include an Unfavorable Impact of $0.11 Per Share Related to Acquired IPR D and Milestones Expense⁴ Delivers Third-Quarter Net Revenues of $17.404 Billion, an Increase of 10.3 Percent on a Reported Basis³ or 10.5 Percent on an Operational Basis Third-Quarter Global Net Revenues from the Immunology Portfolio Were $9.165 Billion, an Increase of 16.3 Percent on a Reported Basis⁵, or 16.6 Percent on an Operational Basis Global Skyrizi Net Revenues Were $5.776 Billion Global Rinvoq Net Revenues Were $2.706 Billion Global Humira Net Revenues Were $683 Million Third-Quarter Global Net Revenues from the Neuroscience Portfolio Were $3.389 Billion, an Increase of 19.4 Percent on a Reported Basis⁶, or 19.5 Percent on an Operational Basis Global Vraylar Net Revenues Were $1.068 Billion Global Botox Therapeutic Net Revenues Were $1.080 Billion Combined Global Ubrelvy and Qulipta Net Revenues Were $847 Million Global Vyalev Net Revenues Were $286 Million Third-Quarter Global Net Revenues from the Oncology Portfolio Were $1.696 Billion, an Increase of 0.8 Percent on a Reported Basis⁷, or 0.9 Percent on an Operational Basis Global Ven

Similar companies

Same SIC code (2834) and public float over $2B, nearest public float first, as each company reports it on its annual report cover.

Johnson & Johnson JNJ public float $367.0B, Jun 29, 2025
Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
Merck MRK public float $198.1B, Jun 30, 2025
Pfizer PFE public float $138.0B, Jun 29, 2025
Vertex Pharmaceuticals VRTX public float $113.4B, Jun 30, 2025